CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T, Morimoto T, Maeoka R, Matsuda R, Nakamura M, Nishimura F, Ouji N, Yamada S, Nakagawa I, Park YS, Ito T, Nakase H, Tsujimura T.
Nakazawa T, et al. Among authors: maeoka r.
J Exp Clin Cancer Res. 2023 Aug 10;42(1):205. doi: 10.1186/s13046-023-02770-6.
J Exp Clin Cancer Res. 2023.
PMID: 37563692
Free PMC article.